MSB

14.3%

$1.06

MESOBLAST LIMITED

Market Cap $1.181B Add to my watchlist

Healthcare Biotechnology

Mesoblast Limited is an Australia-based is developing a range of late-stage product... Mesoblast Limited is an Australia-based is developing a range of late-stage product candidates derived from its proprietary mesenchymal lineage cell therapy technology platforms. The Company’s Remestemcel-L is mesenchymal lineage stromal cell product platform and is in late-stage development for treatment of systemic inflammatory diseases, including Pediatric steroid refractory acute Graft versus Host Disease (SR-aGVHD), acute respiratory distress syndrome (ARDS) and Biologic refractory inflammatory bowel disease. Its Rexlemestrocel-L is mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of advanced chronic heart failure (CHF) and chronic low back pain (CLBP) due to degenerative disc disease. Two products are commercialized in Japan and Europe by the Company’s licensees, and it has a commercial partnership in Europe and China for certain Phase III assets.More

RCE'S BREAKTHROUGH

Recce Pharmaceuticals (ASX:RCE) is stepping up its trial activities in Australia’s nearest Asian neighbour, Indonesia. Recce’s flagship anti-infective, R327, can be applied as a gel – and this gel-based version of the drug has been of specific interest...

Latest Threads

Tag

Subject

MSB

ASX Hot too!

2 3 4

15:31

202

59K

15:31

Last post unlockrobin

202

59K

MSB

MESO Nasdaq update

84 85 86

15:26

5.1K

2.5M

15:26

Last post Lopez

5.1K

2.5M

MSB

banter and General Discussion

157 158 159

14:50

9.5K

2.8M

14:50

Last post dyode

9.5K

2.8M

MSB

MSB $1 Party

18 19 20

14:11

1.1K

331K

14:11

Last post BlingSter

1.1K

331K

MSB

Valuation

10:03

34K

10:03

Last post Fastback6666

34K

MSB

Cell Therapy News/Articles

293 294 295

28/04/24

17K

6.6M

28/04/24

Last post nippy

17K

6.6M

MSB

NASDAQ hot!!!

8 9 10

27/04/24

545

216K

27/04/24

Last post nippy

545

216K

MSB

Mesoblast stock(rock)-take March 2024

3 4 5

24/04/24

272

113K

24/04/24

Last post sponge_

272

113K

See All Discussions

Timeline

Appendix 3Y for Jane Bell
16 Apr 09:18	Share

Application for quotation of securities - MSB
16 Apr 09:15	Share

Notification regarding unquoted securities - MSB
16 Apr 09:06	Share

Notification of cessation of securities - MSB
15 Apr 17:02	Share

Change in substantial holding
09 Apr 09:23	Share

Change in substantial holding
02 Apr 09:53	Share

FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
26 Mar 13:05	Share

Pause in Trading
26 Mar 09:52	Share

Cleansing Notice
26 Mar 09:48	Share

Application for quotation of securities - MSB
22 Mar 16:32	Share

Change in substantial holding
20 Mar 09:46	Share

Proposed issue of securities - MSB
20 Mar 09:37	Share

Cleansing Notice
19 Mar 08:45	Share

Appendix 2A
18 Mar 12:09	Share

Proposed issue of securities - MSB
14 Mar 16:55	Share

Mesoblast Completes Placement and Entitlement Offer
14 Mar 09:54	Share

FDA Supports Accelerated Approval Pathway for Heart Failure
11 Mar 09:57	Share

MSB Q2 Financial Results and Operational Highlights
29 Feb 08:54	Share

Half Year Financial Results Presentation
29 Feb 08:49	Share

Half Year Report and Accounts (including Appendix 4D)
29 Feb 08:46	Share

Mesoblast 2024 Half Year Financial Results Webcast
26 Feb 17:00	Share

FDA Grants Orphan Drug Designation for Revascor
15 Feb 10:46	Share

Quarterly Activities/Appendix 4C Cash Flow Report
31 Jan 12:39	Share

FDA Grants Rare Pediatric Disease Designation for Revascor
19 Jan 09:56	Share

App 3Ys S Itescu,E Rose,J Swedish,B Burns,J Bell,P Facchina
15 Jan 17:33	Share

Notification regarding unquoted securities - MSB
15 Jan 17:19	Share

Notification of cessation of securities - MSB
15 Jan 17:11	Share

Appendix 3Y for Joseph Swedish
03 Jan 17:23	Share

Amended Appendix 3Gs for Unquoted Warrants
03 Jan 17:19	Share

Update on Institutional Placement and Entitlement Offer
28 Dec 11:03	Share

View More

(20min delay)
Last $1.06		Change 0.133(14.3%)		Mkt cap ! $1.181B

Open	High	Low	Value	Volume
95.0¢	$1.07	94.0¢	$14.39M	14.31M

Buyers (Bids)

No.	Vol.	Price($)
21	52267	$1.06

Sellers (Offers)

Price($)	Vol.	No.
$1.07	32864	5

View Market Depth

No.	Vol.	Price($)
22	51731	1.060
15	71727	1.055
19	127612	1.050
14	146797	1.045
14	227567	1.040

Price($)	Vol.	No.
1.065	28864	5
1.070	357668	12
1.075	84699	7
1.080	123683	12
1.090	189711	8

Last trade - 15.09pm 29/04/2024 (20 minute delay)


Last $1.07		Change 0.133 ( 15.8 %)
Open	High	Low	Volume
94.0¢	$1.08	94.0¢	2779353
Last updated 15.28pm 29/04/2024 ?

MSB (ASX) Chart

MESOBLAST LIMITED

Latest Threads

Discover how The Calmer Co. is setting the pace in the fast-growing natural health sector!

Timeline

Featured News

Latest Videos

Mesoblast (ASX:MSB) flags strengthened heart function in latest trial results

28 Feb 2023 10:07 (AEDT)

Latest Articles

Mesoblast (ASX:MSB) completes $97M funding round heading into Q2

Mesoblast (ASX:MSB) has completed its pro-rata accelerated non-renounceable entitlement offer, launched on December 4, 2023.

Mesoblast (ASX:MSB) gains FDA approval to fast-track Revascor in end-stage heart failure

Mesoblast (ASX:MSB) has received U.S. FDA approval to accelerate rexlemestrocel-L (Revascor) for patients with end-stage ischemic heart failure and reduced ejection fraction (HFrEF) with a left ventricular assist device (LVAD).

US FDA grants Mesoblast orphan-drug designation for Revascor

Mesoblast (ASX:MSB) has been granted ODD and RPDD from the United States FDA for its allogeneic cell therapy, Revascor.

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News